303 related articles for article (PubMed ID: 32391193)
21. LILRB1
Xu X; Yin S; Wang Y; Zhu Q; Zheng G; Lu Y; Li T; Zhu C
Int Immunopharmacol; 2023 Jun; 119():110162. PubMed ID: 37075669
[TBL] [Abstract][Full Text] [Related]
22. Pan-Cancer Analysis of Immune Cell Infiltration Identifies a Prognostic Immune-Cell Characteristic Score (ICCS) in Lung Adenocarcinoma.
Zuo S; Wei M; Wang S; Dong J; Wei J
Front Immunol; 2020; 11():1218. PubMed ID: 32714316
[No Abstract] [Full Text] [Related]
23. Naturally Killing the Silent Killer: NK Cell-Based Immunotherapy for Ovarian Cancer.
Nersesian S; Glazebrook H; Toulany J; Grantham SR; Boudreau JE
Front Immunol; 2019; 10():1782. PubMed ID: 31456796
[TBL] [Abstract][Full Text] [Related]
24. Pan-cancer analyses and molecular subtypes based on the cancer-associated fibroblast landscape and tumor microenvironment infiltration characterization reveal clinical outcome and immunotherapy response in epithelial ovarian cancer.
Zou R; Jiang Q; Jin T; Chen M; Yao L; Ding H
Front Immunol; 2022; 13():956224. PubMed ID: 36032075
[TBL] [Abstract][Full Text] [Related]
25. An EMT-based gene signature enhances the clinical understanding and prognostic prediction of patients with ovarian cancers.
Li QJ; Wu ZL; Wang J; Jiang J; Lin B
J Ovarian Res; 2023 Mar; 16(1):51. PubMed ID: 36907877
[TBL] [Abstract][Full Text] [Related]
26. Molecular Features, Prognostic Value, and Cancer Immune Interactions of Angiogenesis-Related Genes in Ovarian Cancer.
Ji Y; Ge Q; Zhang W; Qu P
Reprod Sci; 2023 May; 30(5):1637-1650. PubMed ID: 36471217
[TBL] [Abstract][Full Text] [Related]
27. Three Genes Predict Prognosis in Microenvironment of Ovarian Cancer.
Guo Y; Wang YL; Su WH; Yang PT; Chen J; Luo H
Front Genet; 2020; 11():990. PubMed ID: 32983229
[TBL] [Abstract][Full Text] [Related]
28. Prognostic impact of tumour-associated B cells and plasma cells in epithelial ovarian cancer.
Lundgren S; Berntsson J; Nodin B; Micke P; Jirström K
J Ovarian Res; 2016 Apr; 9():21. PubMed ID: 27048364
[TBL] [Abstract][Full Text] [Related]
29. Modulating the tumor immune microenvironment with nanoparticles: A sword for improving the efficiency of ovarian cancer immunotherapy.
Xu T; Liu Z; Huang L; Jing J; Liu X
Front Immunol; 2022; 13():1057850. PubMed ID: 36532066
[TBL] [Abstract][Full Text] [Related]
30. Prognostic value of immune-related cells and genes in the tumor microenvironment of ovarian cancer, especially CST4.
Wang S; Wang C; Liu O; Hu Y; Li X; Lin B
Life Sci; 2021 Jul; 277():119461. PubMed ID: 33811900
[TBL] [Abstract][Full Text] [Related]
31. Integrated analysis of single-cell RNA-seq and bulk RNA-seq unveils heterogeneity and establishes a novel signature for prognosis and tumor immune microenvironment in ovarian cancer.
Wang Z; Zhang J; Dai F; Li B; Cheng Y
J Ovarian Res; 2023 Jan; 16(1):12. PubMed ID: 36642706
[TBL] [Abstract][Full Text] [Related]
32. A novel DNA methylation-related gene signature for the prediction of overall survival and immune characteristics of ovarian cancer patients.
Wang S; Fu J; Fang X
J Ovarian Res; 2023 Mar; 16(1):62. PubMed ID: 36978087
[TBL] [Abstract][Full Text] [Related]
33. Comprehensive characterization of the alternative splicing landscape in ovarian cancer reveals novel events associated with tumor-immune microenvironment.
Sun D; Zhao X; Yu Y; Li W; Gu P; Zhi Z; Xu D
Biosci Rep; 2022 Feb; 42(2):. PubMed ID: 35137909
[TBL] [Abstract][Full Text] [Related]
34. Identification of peripheral blood immune infiltration signatures and construction of monocyte-associated signatures in ovarian cancer and Alzheimer's disease using single-cell sequencing.
Zhao S; Ye B; Chi H; Cheng C; Liu J
Heliyon; 2023 Jul; 9(7):e17454. PubMed ID: 37449151
[TBL] [Abstract][Full Text] [Related]
35. Metabolism-related gene vaccines and immune infiltration in ovarian cancer: A novel risk score model of machine learning.
Fu Y; Huang Z; Huang J; Xiong J; Liu H; Wan X
J Gene Med; 2024 Jan; 26(1):e3568. PubMed ID: 37455244
[TBL] [Abstract][Full Text] [Related]
36. Prognostic significance of tumor-associated macrophages in ovarian cancer: A meta-analysis.
Yuan X; Zhang J; Li D; Mao Y; Mo F; Du W; Ma X
Gynecol Oncol; 2017 Oct; 147(1):181-187. PubMed ID: 28698008
[TBL] [Abstract][Full Text] [Related]
37. Identification of an Immune-Related Prognostic Gene CLEC5A Based on Immune Microenvironment and Risk Modeling of Ovarian Cancer.
Shen J; Liu T; Lv J; Xu S
Front Cell Dev Biol; 2021; 9():746932. PubMed ID: 34712666
[No Abstract] [Full Text] [Related]
38. A risk model based on the tumor microenvironment to predict survival and immunotherapy efficacy for ovarian cancer.
Wang YR; Wu WL; Cheng X; Gao HX; Li W; Liu ZY
Eur Rev Med Pharmacol Sci; 2023 Dec; 27(23):11614-11634. PubMed ID: 38095409
[TBL] [Abstract][Full Text] [Related]
39. Identification and Validation of Immune-Related Gene for Predicting Prognosis and Therapeutic Response in Ovarian Cancer.
Zhang ZC; Guo JN; Zhang N; Wang ZQ; Lou G; Cui BB; Yang C
Front Immunol; 2021; 12():763791. PubMed ID: 34880862
[TBL] [Abstract][Full Text] [Related]
40. Signatures of tumor-associated macrophages correlate with treatment response in ovarian cancer patients.
Gao Y; Qi Y; Shen Y; Zhang Y; Wang D; Su M; Liu X; Wang A; Zhang W; He C; Yang J; Dai M; Wang H; Cai H
Aging (Albany NY); 2024 Jan; 16(1):207-225. PubMed ID: 38175687
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
